Joshua Waytz, MD
Rheumatology · Edina, MNNPI 1619460854
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,680 of the $1,933 with a category attached, or 86.9%. Johnson & Johnson accounts for 95.0% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2024 at $1,883 and has fallen 99.0% since, to $20 in 2025.
Across 9 payments — averaging $214.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Organon$30
- Amgen$20
- Boehringer Ingelheim$18
- Aurinia Pharma U.S., Inc.$16
- Fresenius Kabi USA, LLC$13
What the payments were for
- Consulting fees$1,68087%
- Food & beverage$25313%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 4 | $1,836 |
| Organon | 1 | $30 |
| Amgen | 1 | $20 |
| Boehringer Ingelheim | 1 | $18 |
| Aurinia Pharma U.S., Inc. | 1 | $16 |
| Fresenius Kabi USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$1,816
How this compares
$1,933 in reported general payments places this provider in the 75th percentile of 121 rheumatology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 32 | $309,476 |
| Humira PenAdalimumab | 11 | $71,495 |
| MethotrexateMethotrexate Sodium | 277 | $8,108 |
| Hydroxychloroquine Sulfate | 135 | $6,373 |
| Leflunomide | 40 | $4,139 |
| Prednisone | 298 | $2,724 |
| Azathioprine | 31 | $1,607 |
| Sulfasalazine | 21 | $1,240 |
| Tramadol Hcl | 58 | $669 |
| Gabapentin | 20 | $667 |
| Salsalate | 11 | $661 |
| Allopurinol | 33 | $380 |
| Alendronate Sodium | 14 | $253 |
| Meloxicam | 44 | $249 |
| Celecoxib | 12 | $158 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Edina
- Jeffrey WilsonEdina$49K
- Sara BaigEdina$2K
- Grace Skemp-DymondEdina$2K
- Angela DahleEdina$1K
- Kurt ZimmermanEdina$1K
- Susan LeonardEdina$485
- Walter DormanEdina$403
- Hammad BajwaEdina$248
- Donna FontanaEdina$191
- Anne WolffEdina$184
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.